JBM (Healthcare) Ltd. (HK:2161)
:2161
Want to see HK:2161 full AI Analyst Report?
2161 Stock Chart & Stats
HK$2.77
-HK$0.02(-1.12%)
At close: 4:00 PM EST
HK$2.77
-HK$0.02(-1.12%)
Day’s Range― - ―
52-Week RangeHK$2.07 - HK$3.43
Previous CloseN/A
Volume460.00K
Average Volume (3M)599.79K
Market Cap
HK$1.98B
Enterprise ValueHK$2.22B
Total Cash (Recent Filing)HK$194.20M
Total Debt (Recent Filing)HK$383.18M
Price to Earnings (P/E)5.3
Beta0.08
Next Earnings
Jun 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield9.98%
Share Statistics
EPS (TTM)0.14
Shares Outstanding822,000,000
10 Day Avg. Volume515,131
30 Day Avg. Volume599,792
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.36
Price to Sales (P/S)1.87
P/FCF Ratio7.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.15Price Target Upside13.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.33
Revenue Forecast (FY)HK$953.48M
Bulls Say, Bears Say
Bulls Say
High Profitability MarginsSustained high gross and net margins plus strong EBIT/EBITDA imply durable pricing power and efficient operations. These margins support persistent cash generation, allow reinvestment in the business, and provide a buffer against cost volatility over the next several quarters.
Low Leverage And Strong Capital StructureVery low leverage and a high equity ratio provide financial flexibility and resilience. A strong ROE indicates effective capital deployment. This balance sheet strength supports capex, strategic investments, or downturn absorption without stressing liquidity over the medium term.
Consistent Revenue And EPS GrowthDouble-digit revenue expansion alongside substantial EPS growth signals sustained demand and operational leverage. Continued top-line growth with improving per-share earnings points to scalable economics and the potential to compound shareholder value over a 2–6 month horizon.
Bears Say
Declining Free Cash Flow GrowthA nearly 20% drop in free cash flow growth is a structural concern if it persists, reducing the company's ability to self-fund capex, R&D or distributions. Sustained FCF decline forces tougher capital allocation choices and could increase reliance on external financing.
Cash Conversion Below Reported EarningsOCF and FCF below net income indicate earnings are not fully converting to cash, suggesting working capital or accruals pressure. Persistent cash conversion gaps can constrain real liquidity for investment or dividends and weaken financial resilience over the medium term.
Relatively Small Operating ScaleA modest headcount suggests limited scale in R&D, manufacturing and commercial reach relative to larger peers. In specialty & generic drug markets, scale drives cost, supply and geographic expansion advantages; limited scale may cap growth and competitiveness over several quarters.
JBM (Healthcare) Ltd. News
2161 FAQ
What was JBM (Healthcare) Ltd.’s price range in the past 12 months?
JBM (Healthcare) Ltd. lowest stock price was HK$2.07 and its highest was HK$3.43 in the past 12 months.
What is JBM (Healthcare) Ltd.’s market cap?
JBM (Healthcare) Ltd.’s market cap is HK$1.98B.
When is JBM (Healthcare) Ltd.’s upcoming earnings report date?
JBM (Healthcare) Ltd.’s upcoming earnings report date is Jun 11, 2026 which is in 43 days.
How were JBM (Healthcare) Ltd.’s earnings last quarter?
JBM (Healthcare) Ltd. released its earnings results on Nov 17, 2025. The company reported HK$0.141 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.141.
Is JBM (Healthcare) Ltd. overvalued?
According to Wall Street analysts JBM (Healthcare) Ltd.’s price is currently Undervalued.
Does JBM (Healthcare) Ltd. pay dividends?
JBM (Healthcare) Ltd. pays a Quarterly dividend of HK$0.098 which represents an annual dividend yield of 9.98%. See more information on JBM (Healthcare) Ltd. dividends here
What is JBM (Healthcare) Ltd.’s EPS estimate?
JBM (Healthcare) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JBM (Healthcare) Ltd. have?
JBM (Healthcare) Ltd. has 822,000,000 shares outstanding.
What happened to JBM (Healthcare) Ltd.’s price movement after its last earnings report?
JBM (Healthcare) Ltd. reported an EPS of HK$0.141 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.449%.
Which hedge fund is a major shareholder of JBM (Healthcare) Ltd.?
Currently, no hedge funds are holding shares in HK:2161
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JBM (Healthcare) Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
218.77%
12-Months-Change
Fundamentals
Return on Equity
20.10%
Trailing 12-Months
Asset Growth
25.71%
Trailing 12-Months
Company Description
JBM (Healthcare) Ltd.
JBM (Healthcare) Limited, an investment holding company, develops, manufactures, markets, distributes, and sells healthcare and wellness products in Asia. The company offers consumer healthcare and proprietary Chinese medicines, such as over-the-counter medicines, and medicated and non-medicated solutions, as well as diagnostic devices; and pharmaceutical products. It is also involved in the trading, wholesaling, and retailing of Chinese medicines; trading of medical supplies and pharmaceutical products; and sale of healthcare and herbal products. The company was incorporated in 2020 and is headquartered in Kwun Tong, Hong Kong. JBM (Healthcare) Limited is a subsidiary of JBM Group (BVI) Limited.
2161 Stock 12 Month Forecast
Average Price Target
HK$3.15
▲(13.72% Upside)
Technical Analysis
PuraPharm Corp. Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Jacobson Pharma Corporation Limited
―
Zhongzhi Pharmaceutical Holdings Limited
―
Options Prices
Currently, No data available
---